Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/23/2026

1. SPY
2. KBH
3. PATH
4. USO
5. AZO

6. QQQ
7. META
8. ORCL
9. RCL
10. ONON

Get Alerts PRLD Hot Sheet

Price: $4.31 -11.13%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

WILMINGTON, Del., June 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences:

42nd Annual Goldman Sachs Global Healthcare Conference

Fireside chat at 8:00 a.m. ET on Wednesday, June 9, 2021

JMP Securities Life Sciences Conference

Corporate presentation at 10:00 a.m. ET on Wednesday, June 16, 2021

A live webcast of the Goldman Sachs fireside chat and JMP Securities presentation can be accessed under “Events & Presentations” in the Investor Section of the Company’s website, https://investors.preludetx.com/news-and-events/events-and-presentations, where a replay of the events will also be available for a limited time.

About Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.

Contact

Investors: Melissa ForstMedia: Deborah ElsonArgot Partners212.600.1902[email protected]